Discontinuation report STEGLUJAN
Report ID | 133310 |
Drug Identification Number | 02475901 |
Brand name | STEGLUJAN |
Common or Proper name | Ertugliflozin Sitagliptin tablets |
Company Name | MERCK CANADA INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | ERTUGLIFLOZIN SITAGLIPTIN |
Strength(s) | 5MG 100MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 30 |
ATC code | A10BD |
ATC description | |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | |
Actual discontinuation date | 2021-02-03 |
Remaining supply date | 2021-02-03 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 16750 ROUTE TRANSCANADIENNE KIRKLAND, QUEBEC CANADA H9H 4M7 |
Company contact information | 1-800-567-2594 medinfocanada@merck.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v2 | 2021-02-04 | French | Compare |
v1 | 2021-02-04 | English | Compare |
Showing 1 to 2 of 2